Eiger BioPharmaceuticals’ (NASDAQ:EIGR) Buy Rating Reiterated at Wedbush

Wedbush reiterated their buy rating on shares of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) in a report released on Wednesday, October 25th.

EIGR has been the subject of a number of other reports. Oppenheimer Holdings, Inc. set a $34.00 price target on Eiger BioPharmaceuticals and gave the stock a buy rating in a report on Monday, October 23rd. Zacks Investment Research raised Eiger BioPharmaceuticals from a hold rating to a buy rating and set a $15.00 price target for the company in a report on Monday, October 16th. BTIG Research started coverage on Eiger BioPharmaceuticals in a research report on Friday, July 14th. They set a buy rating and a $32.00 target price on the stock. Roth Capital started coverage on Eiger BioPharmaceuticals in a research report on Thursday, October 19th. They set a buy rating and a $35.00 target price on the stock. Finally, ValuEngine upgraded Eiger BioPharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $30.43.

Eiger BioPharmaceuticals (NASDAQ:EIGR) opened at $10.85 on Wednesday. Eiger BioPharmaceuticals has a fifty-two week low of $6.10 and a fifty-two week high of $13.95. The company has a quick ratio of 5.78, a current ratio of 5.78 and a debt-to-equity ratio of 1.19.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.28) by $0.18. sell-side analysts predict that Eiger BioPharmaceuticals will post -5.35 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by BBNS and is the property of of BBNS. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/eiger-biopharmaceuticals-inc-eigr-given-buy-rating-at-wedbush/1736093.html.

In other Eiger BioPharmaceuticals news, Director Jeffrey S. Glenn bought 15,000 shares of the company’s stock in a transaction on Friday, September 1st. The shares were bought at an average price of $9.53 per share, for a total transaction of $142,950.00. Following the transaction, the director now owns 31,355 shares of the company’s stock, valued at approximately $298,813.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 28.80% of the company’s stock.

Large investors have recently made changes to their positions in the company. Wedbush Securities Inc. purchased a new stake in shares of Eiger BioPharmaceuticals during the 3rd quarter worth approximately $114,000. JPMorgan Chase & Co. lifted its stake in Eiger BioPharmaceuticals by 295.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,705 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 8,748 shares in the last quarter. OxFORD Asset Management LLP purchased a new stake in Eiger BioPharmaceuticals in the 3rd quarter valued at approximately $147,000. Bank of New York Mellon Corp lifted its stake in Eiger BioPharmaceuticals by 4.7% in the 1st quarter. Bank of New York Mellon Corp now owns 13,696 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 614 shares in the last quarter. Finally, Susquehanna International Group LLP purchased a new stake in Eiger BioPharmaceuticals in the 2nd quarter valued at approximately $114,000. 61.04% of the stock is currently owned by institutional investors and hedge funds.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Analyst Recommendations for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.